• Nanexa swung to a profit after tax of SEK 157.38 million in the third quarter of 2026.
• Turnover rose year over year to SEK 227.87 million.
• Signed a EUR 1.17 billion global license and collaboration agreement with Novo for long-acting injectables, including EUR 20 million upfront.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanexa AB published the original content used to generate this news brief on November 05, 2026, and is solely responsible for the information contained therein.